FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2302746114> ?p ?o ?g. }

• W2302746114 abstract "Abstract BACKGROUND: Early treatment with lenalidomide and dexamethasone delays progression and increases overall survival in patients with high-risk smoldering multiple myeloma. The addition of the selective proteasome inhibitor carfilzomib to a lenalidomide and dexamethasone backbone has proven effective in patients with newly-diagnosed multiple myeloma; this combination may allow patients with high-risk smoldering multiple myeloma to obtain deep and durable responses. METHODS: In this phase 2 pilot study, patients with high-risk smoldering multiple myeloma received eight 28-day cycles of induction therapy with carfilzomib (at a dose of 20/36 mg per square meter on days 1, 2, 8, 9, 15, and 16), lenalidomide (at a dose of 25 mg on days 1–21), and dexamethasone (at a dose of 10 or 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23). Patients achieving stable disease or better after combination therapy received 2 years of maintenance therapy with lenalidomide. Minimal residual disease was assessed with multi-color flow cytometry, next-generation sequencing by the LymphoSIGHT method, and fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PET/CT). Myeloma clonotypes were identified in genomic DNA obtained from CD138+ bone marrow cell lysate or cell-free bone marrow aspirate at baseline for each patient based on their high frequency within the B-cell repertoire. Per study protocol, minimal residual disease assessment by next-generation sequencing, multi-color flow cytometry and FDG-PET/CT was repeated when patients achieved a complete response or completed 8 cycles of induction treatment. A sample size of 12 evaluable patients was calculated as being minimally necessary based on the following probability calculations: If the true probability of a very good partial response was 20% or 50%, we calculated that there would be a 7.3% or 80.6% probability, respectively, if 5 or more patients exhibiting a very good partial response (VGPR). Thus, if 5 or more patients out of 12 achieved a very good partial response, there would be strong evidence that the true probability of a VGPR was 50% or more. RESULTS: Twelve patients were enrolled. All 11 patients (100%) who completed 8 cycles of combination therapy obtained VGPR or better (primary end point). Minimal residual disease assessment by next-generation sequencing was performed on bone marrow supernatant to detect cell-free myeloma clonotypes, while flow cytometry analysis utilized bone marrow cells. Overall (N=12), 100% of patients achieved a complete response or better over the study period, including 11 patients (92%) negative for minimal residual disease based on multi-color flow cytometry. Based on next-generation sequencing, two of the 12 patients were positive for minimal residual disease in the bone marrow supernatant; one of these two patients was also positive for minimal residual disease based on multi-color flow cytometry in the bone marrow cells. Information regarding longitudinal minimal residual disease status will be available and presented at the meeting. Adverse events were manageable. CONCLUSIONS: Early treatment with carfilzomib, lenalidomide, and dexamethasone was associated with high rates of complete response and minimal residual disease negativity by multi-color flow cytometry, next-generation sequencing, and FDG-PET/CT in patients with high-risk smoldering multiple myeloma. Disclosures Landgren: Onyx Pharmaceuticals: Consultancy; Medscape: Consultancy; Millennium Pharmaceuticals: Independent Data Monitoring Committee (IDMC), Independent Data Monitoring Committee (IDMC) Other. Off Label Use: Carfilzomib and lenalidomide for high-risk smoldering multiple myeloma." @default.
• W2302746114 created "2016-06-24" @default.
• W2302746114 creator A5001321994 @default.
• W2302746114 creator A5010930696 @default.
• W2302746114 creator A5014636271 @default.
• W2302746114 creator A5016656825 @default.
• W2302746114 creator A5017057018 @default.
• W2302746114 creator A5026364677 @default.
• W2302746114 creator A5033364146 @default.
• W2302746114 creator A5035197055 @default.
• W2302746114 creator A5044239219 @default.
• W2302746114 creator A5044366730 @default.
• W2302746114 creator A5044681793 @default.
• W2302746114 creator A5045179755 @default.
• W2302746114 creator A5046553822 @default.
• W2302746114 creator A5046878636 @default.
• W2302746114 creator A5048088566 @default.
• W2302746114 creator A5048966043 @default.
• W2302746114 creator A5058021865 @default.
• W2302746114 creator A5060701531 @default.
• W2302746114 creator A5061379753 @default.
• W2302746114 creator A5062086023 @default.
• W2302746114 creator A5064222660 @default.
• W2302746114 creator A5065696086 @default.
• W2302746114 creator A5067074464 @default.
• W2302746114 creator A5079704265 @default.
• W2302746114 creator A5081833588 @default.
• W2302746114 creator A5081837203 @default.
• W2302746114 creator A5082004555 @default.
• W2302746114 creator A5082376289 @default.
• W2302746114 creator A5086510250 @default.
• W2302746114 creator A5087722453 @default.
• W2302746114 creator A5089952063 @default.
• W2302746114 date "2014-12-06" @default.
• W2302746114 modified "2023-09-26" @default.
• W2302746114 title "Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study" @default.
• W2302746114 doi "https://doi.org/10.1182/blood.v124.21.4746.4746" @default.
• W2302746114 hasPublicationYear "2014" @default.
• W2302746114 type Work @default.
• W2302746114 sameAs 2302746114 @default.
• W2302746114 citedByCount "6" @default.
• W2302746114 countsByYear W23027461142015 @default.
• W2302746114 countsByYear W23027461142016 @default.
• W2302746114 countsByYear W23027461142017 @default.
• W2302746114 crossrefType "journal-article" @default.
• W2302746114 hasAuthorship W2302746114A5001321994 @default.
• W2302746114 hasAuthorship W2302746114A5010930696 @default.
• W2302746114 hasAuthorship W2302746114A5014636271 @default.
• W2302746114 hasAuthorship W2302746114A5016656825 @default.
• W2302746114 hasAuthorship W2302746114A5017057018 @default.
• W2302746114 hasAuthorship W2302746114A5026364677 @default.
• W2302746114 hasAuthorship W2302746114A5033364146 @default.
• W2302746114 hasAuthorship W2302746114A5035197055 @default.
• W2302746114 hasAuthorship W2302746114A5044239219 @default.
• W2302746114 hasAuthorship W2302746114A5044366730 @default.
• W2302746114 hasAuthorship W2302746114A5044681793 @default.
• W2302746114 hasAuthorship W2302746114A5045179755 @default.
• W2302746114 hasAuthorship W2302746114A5046553822 @default.
• W2302746114 hasAuthorship W2302746114A5046878636 @default.
• W2302746114 hasAuthorship W2302746114A5048088566 @default.
• W2302746114 hasAuthorship W2302746114A5048966043 @default.
• W2302746114 hasAuthorship W2302746114A5058021865 @default.
• W2302746114 hasAuthorship W2302746114A5060701531 @default.
• W2302746114 hasAuthorship W2302746114A5061379753 @default.
• W2302746114 hasAuthorship W2302746114A5062086023 @default.
• W2302746114 hasAuthorship W2302746114A5064222660 @default.
• W2302746114 hasAuthorship W2302746114A5065696086 @default.
• W2302746114 hasAuthorship W2302746114A5067074464 @default.
• W2302746114 hasAuthorship W2302746114A5079704265 @default.
• W2302746114 hasAuthorship W2302746114A5081833588 @default.
• W2302746114 hasAuthorship W2302746114A5081837203 @default.
• W2302746114 hasAuthorship W2302746114A5082004555 @default.
• W2302746114 hasAuthorship W2302746114A5082376289 @default.
• W2302746114 hasAuthorship W2302746114A5086510250 @default.
• W2302746114 hasAuthorship W2302746114A5087722453 @default.
• W2302746114 hasAuthorship W2302746114A5089952063 @default.
• W2302746114 hasConcept C126322002 @default.
• W2302746114 hasConcept C143998085 @default.
• W2302746114 hasConcept C2776063141 @default.
• W2302746114 hasConcept C2776364478 @default.
• W2302746114 hasConcept C2779823535 @default.
• W2302746114 hasConcept C2780007613 @default.
• W2302746114 hasConcept C2780108899 @default.
• W2302746114 hasConcept C2780401358 @default.
• W2302746114 hasConcept C2989005 @default.
• W2302746114 hasConcept C71924100 @default.
• W2302746114 hasConcept C90924648 @default.
• W2302746114 hasConceptScore W2302746114C126322002 @default.
• W2302746114 hasConceptScore W2302746114C143998085 @default.
• W2302746114 hasConceptScore W2302746114C2776063141 @default.
• W2302746114 hasConceptScore W2302746114C2776364478 @default.
• W2302746114 hasConceptScore W2302746114C2779823535 @default.
• W2302746114 hasConceptScore W2302746114C2780007613 @default.
• W2302746114 hasConceptScore W2302746114C2780108899 @default.
• W2302746114 hasConceptScore W2302746114C2780401358 @default.
• W2302746114 hasConceptScore W2302746114C2989005 @default.
• W2302746114 hasConceptScore W2302746114C71924100 @default.
• W2302746114 hasConceptScore W2302746114C90924648 @default.
• W2302746114 hasLocation W23027461141 @default.
• W2302746114 hasOpenAccess W2302746114 @default.

• next